Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

(Reuters) -Drugmaker Regeneron Pharmaceuticals is acquiring majority assets of bankrupt genetic testing firm 23andMe Holding for $256 million. The once-sizzling DNA-testing startup filed for ...

CEO Lars Fruergaard Jørgensen is stepping down after eight years in the role, during which he led the company to an all-time ...

Novo Nordisk's (NVO) investors are worried its competition ... according to the latest prescription data last month. But Novo CEO Lars Jørgensen attributes the softness in sales to the copycats ...

Rapport Therapeutics CEO Abe Ceesay ... Catalent was acquired by Novo Holdings – the investment firm and holding company managing the assets of the Novo Nordisk Foundation which owns Novo Nordisk – at ...

Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the US to start to recover once a ban on compound copycats is enforced this month, its CEO said today after the company cut its 2025 ...

while Novo Nordisk said CVS approached the drugmaker about the Wegovy agreement, according to Seigerman. On an earnings call on Thursday, Eli Lilly CEO David Ricks said the company has been trying ...

The main story of the earnings report was Novo Nordisk's 2025 guidance, which calls for sales to grow from 13% to 21%. CEO Lars Fruergaard Jorgensen said that the company is "actively focused on ...

On Wednesday, BofA Securities revised its price target for Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO) shares, lowering it to DKK850 from the previous DKK910. Despite the reduction, the firm ...